This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Safety Concern Halts Study of Seattle Genetics' Lymphoma Drug

SEATTLE ( TheStreet) -- A small clinical study treating elderly Hodgkin lymphoma patients with a combination of Seattle Genetics' (SGEN - Get Report) Adcetris and chemotherapy has been stopped temporarily due to reports of pancreatitis, a dangerous swelling of the pancreas, the company confirmed Tuesday.

The decision to suspend patient enrollment in the Adcetris study due to concerns about pancreatitis was made by researchers at Chicago's Northwestern University, which designed and is conducting the study. Seattle Genetics says none of its Adcetris studies have been halted for any toxicity reasons.

JMP Securities first picked up on the Adcetris study halt Friday following a presentation by Northwestern's Dr. Andrew Evens at a lymphoma research meeting in Lugano, Switzerland. As word filtered back through Wall Street Friday, Seattle Genetics shares sold off moderately. The stock recovered partially by the close of Friday trading after Seattle Genetics denied any knowledge of an Adcetris study being halted due to safety concerns.

Now, the company admits its denial Friday was a mistake.

"We looked into this further, and Dr. Evens apparently made a comment on Friday at the ICML conference in Lugano, Switzerland that he had observed some pancreatitis in an investigator-sponsored trial of Adcetris," said company spokeswoman Tricia Larson, in an email statement. "Currently, enrollment in that investigator-sponsored trial is on temporary hold, with the intention of reopening in the near future. None of our corporate trials of Adcetris have been halted for any toxicity reasons."

The phase II study in question is enrolling patients 60 years or older with previously untreated Hodgkin lymphoma. The patients are treated first with Adcetris, followed by a chemotherapy cocktail containing adriamycin, vinblastine and dacarbazine, colloquially known as AVD.

The rate and severity of the pancreatitis observed in the study has not been disclosed. Evens did not respond to an email requesting comment.

Pancreatitis is a "rare, known adverse event in patients treated with Adcetris," said Seattle Genetics' Larson.

Adcetris was approved in 2011 for two different types of lymphoma, including Hodgkin, but only in patients no longer responding to previously approved treatments. Seattle Genetics is conducting numerous follow-on studies to expand use of Adcetris, including studies of previously untreated Hodgkin lymphoma patients.

One of these Seattle Genetics' phase III studies -- dubbed "Echelon-1" -- uses the same Adcetris plus AVD chemotherapy regimen as the study halted by Northwestern.

Another company-sponsored phase II study utilizes Adcetris on its own in previously untreated elderly Hodgkin lymphoma patients.

Seattle Genetics reported first-quarter Adcetris net sales of $34 million and said net sales for the entire year would be in the range of $130 million to $140 million, flat with 2012 net sales.

On Tuesday, Seattle Genetics were up 4.5% to $31.26 in early trading after the company announced a new drug development partnership with Bayer.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SGEN $33.18 -0.12%
AAPL $92.82 -0.45%
FB $118.41 0.51%
GOOG $706.00 0.65%
TSLA $211.72 0.09%


Chart of I:DJI
DOW 17,612.02 -48.69 -0.28%
S&P 500 2,040.59 -10.04 -0.49%
NASDAQ 4,687.4980 -29.5960 -0.63%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs